Administration of an anti-lgr5 monoclonal antibody
AssigneeBionomics Limited
InventorsChristopher L. Reyes, Peter Chu, Elizabeth Doolin, Jose Iglesias
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the field of cancer biology. Some embodiments of the methods and compositions provided herein relate to administration of humanized antibodies or antigen-binding fragments thereof that specifically bind to LRG5 to treat certain cancers
Claims28
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a subject having a cancer comprising administering an effective amount of a humanized monoclonal antibody or an antigen-binding fragment thereof that specifically binds leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) to the subject in need thereof, wherein:
- the monoclonal antibody comprises a heavy chain comprising SEQ ID NO:13 and a light chain comprising SEQ ID NO:14;
- the monoclonal antibody is administered weekly for at least 4 weeks;
- the monoclonal antibody is administered intravenously;
- and
- the dosage of the monoclonal antibody is between about 2.5 mg/kg to about 15 mg/kg.
A container comprising a pharmaceutical composition comprising a dose of a humanized monoclonal antibody that specifically binds leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), and a suitable pharmaceutical carrier, wherein the dose of the monoclonal antibody is between about 2.5 mg/kg to about 15 mg/kg.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.